Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Complications

Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin

Bone Marrow Transplantation volume 27, pages 627–633 (2001)Cite this article

Abstract

This retrospective cohort study of 462 consecutive adult allogeneic and autologous blood or marrow transplantation (BMT) patients compared the incidence of hepatic veno-occlusive disease (VOD) after BMT with three prophylactic regimens. Patients receiving heparin (Hep), heparin + prostaglandin E1 (Hep + PGE1) or low molecular weight heparin (LMWH) as a prophylactic VOD regimen were compared to a historical cohort receiving no VOD prophylaxis. Of 462 BMT patients, VOD was diagnosed in 22% (31 of 142) of the no prophylaxis group, 11% (11 of 104) of the Hep, 12% (13 of 110) in the Hep + PGE1 and 4% (four of 106) of the LMWH group (P = 0.0002). VOD was the primary cause of death in 20% (12 of 59). By multivariate logistic regression, independent risk factors for developing VOD were: no VOD prophylactic regimen, unrelated allogeneic BMT, Karnofsky performance score (KPS) <80 and aspartate aminotransferase (AST) ⩾50 U/l. There was no increase in the rate of death due to hemorrhagic events or VOD in any prophylaxis group compared to the control group. Prospective randomized trials of Hep vs LMWH vs placebo are warranted to assess the efficacy of heparin compounds in the prevention of VOD. Bone Marrow Transplantation (2001) 27, 627–633.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. McDonald GB, Sharma P, Matthews DE et al. Venoocclusive disease of the liver after marrow transplantation: diagnosis, incidence, and predisposing factors Hepatology 1984 4: 116–122

    Article  CAS  PubMed  Google Scholar 

  2. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients Ann Intern Med 1993 118: 255–267

    Article  CAS  PubMed  Google Scholar 

  3. Jones RJ, Lee KSK, Beschorner WE et al. Veno-occlusive disease of the liver following bone marrow transplantation Transplantation 1987 44: 778–783

    Article  CAS  PubMed  Google Scholar 

  4. McDonald GB, Sharma P, Matthews DE et al. The clinical course of 53 patients with veno-occlusive disease of the liver after marrow transplantation Transplantation 1985 39: 603–608

    Article  CAS  PubMed  Google Scholar 

  5. Shulman HM, McDonald GB, Matthews D et al. An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation Gastroenterology 1980 79: 1178–1191

    CAS  PubMed  Google Scholar 

  6. Shulman HM, Fisher LB, Schoch HG et al. Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms Hepatology 1994 19: 1171–1181

    Article  CAS  PubMed  Google Scholar 

  7. Attal M, Huguet F, Rubie H et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial Blood 1992 79: 2834–2840

    CAS  PubMed  Google Scholar 

  8. Rosenthal J, Sender L, Secola R et al. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation Bone Marrow Transplant 1996 18: 185–191

    CAS  PubMed  Google Scholar 

  9. Marsa-Vila L, Gorin NC, Laporte JP et al. Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation Eur J Haematol 1991 47: 346–354

    Article  CAS  PubMed  Google Scholar 

  10. Carreras E, Bertz H, Arcese W et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation Blood 1998 92: 2599–3604

    Google Scholar 

  11. Cahn JY, Flesch M, Brion A et al. Prevention of veno-occlusive disease of the liver after bone marrow transplantation: heparin or no heparin? Blood 1992 80: 2149–2150

    CAS  PubMed  Google Scholar 

  12. Bearman SI, Hinds MS, Wolford JL . A pilot study of continuous infusion heparin for the prevention of hepatic veno-occlusive disease after bone marrow transplantation Bone Marrow Transplant 1990 5: 407–411

    CAS  PubMed  Google Scholar 

  13. Gluckman E, Jolivet I, Scrobohaci ML et al. Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation Br J Haematol 1990 74: 277–281

    Article  CAS  PubMed  Google Scholar 

  14. Bearman SI, Shen DD, Hinds MS et al. A phase I/II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation Br J Haematol 1993 84: 724–730

    Article  CAS  PubMed  Google Scholar 

  15. Hull RD, Raskob GE, Pineo GF et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis New Engl J Med 1992 326: 975–982

    Article  CAS  PubMed  Google Scholar 

  16. Spiro TE, Johnson GJ, Christie MJ et al. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery Ann Intern Med 1994 121: 81–89

    Article  CAS  PubMed  Google Scholar 

  17. Or R, Nagler A, Shpilberg O et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients Transplantation 1996 61: 1067–1071

    Article  CAS  PubMed  Google Scholar 

  18. Schriber J, Milk BJ, Baer MR et al. A randomized phase II trial comparing heparin (Hep) +/− Prostaglandin E1 (PG) to prevent hepatotoxicity (HT) following bone marrow transplantation (BMT): preliminary results Blood 1996 88: (Suppl. 1) 413a (Abstr. 1642)

    Google Scholar 

  19. Alidina A, Lawrence D, Ford LA et al. Thiotepa-associated cardiomyopathy during blood or marrow transplantation: association with the female sex and cardiac risk factors Biol BMT 1999 5: 322–327

    CAS  Google Scholar 

  20. Brown RA, Wolff SN, Fay JW et al. High-dose etoposide, cyclophosphamide and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: a study by the North American Marrow Transplant Group Blood 1995 85: 1391–1395

    CAS  PubMed  Google Scholar 

  21. Jagannath S, Armitage JO, Dicke KA et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease J Clin Oncol 1989 7: 179–185

    Article  CAS  PubMed  Google Scholar 

  22. Santos GW, Tutschka PJ, Brookmeyer R . Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide New Engl J Med 1983 309: 1347–1353

    Article  CAS  PubMed  Google Scholar 

  23. Thomas ED, Storb R, Fefer A et al. Aplastic anaemia treated by marrow transplantation Lancet 1972 1: 284–289

    Article  CAS  PubMed  Google Scholar 

  24. Jagannath S, Vesole DH, Glenn L et al. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow transplantation and blood stem cell support Blood 1992 80: 1666–1672

    CAS  PubMed  Google Scholar 

  25. Nash RA, Pepe MS, Storb R et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate Blood 1992 80: 1838–1845

    CAS  PubMed  Google Scholar 

  26. Shepherd JD, Shore TB, Reece DE et al. Cyclosporine and methylprednisolone for prophylaxis of acute graft-versus-host disease Bone Marrow Transplant 1988 3: 553–558

    CAS  PubMed  Google Scholar 

  27. Alam A, Baer MR, Bernstein S et al. Phase II clinical trial of OKT3 for acute graft-versus-host disease (GVHD) prophylaxis in allogeneic bone marrow transplantation (alloBMT) Blood 1997 90: (Suppl. 1) 102a (Abstr. 449)

    Google Scholar 

  28. Chao NJ, Schmidt GM, Niland JC et al. Cyclosporine, methotrexate and prednisone compared with cyclosporine and prednisone for prophylaxis for acute graft-versus-host disease New Engl J Med 1993 329: 1225–1230

    Article  CAS  PubMed  Google Scholar 

  29. Ratanatarathorn V, Nash RA, Przepiorka D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation Blood 1998 92: 2303–2314

    Google Scholar 

  30. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors Transplantation 1974 18: 295–304

    Article  CAS  PubMed  Google Scholar 

  31. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man: a long-term clinico-pathologic study of 20 Seattle patients Am J Med 1980 69: 204–217

    Article  CAS  PubMed  Google Scholar 

  32. Schriber J, Milk B, Shaw D et al. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation Bone Marrow Transplant 1999 24: 1311–1314

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors acknowledge Sandra Dascomb for her assistance with data management.

Author information

Authors and Affiliations

  1. Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA

    M Simon, LA Ford, B Anderson, D Swinnich, MR Baer, B Bambach, SH Bernstein, ZP Bernstein, ZP Bernstein, MS Czuczman, JL Slack, M Wetzler, G Herzig, J Schriber & PL McCarthy Jr

  2. Department of Medicine and Cancer Prevention, Epidemiology and Biostatistics, Roswell Park Cancer Institute, Buffalo, NY, USA

    T Hahn

Authors
  1. M Simon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Hahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. LA Ford
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Swinnich
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. MR Baer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B Bambach
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. SH Bernstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. ZP Bernstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. MS Czuczman
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. JL Slack
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M Wetzler
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. G Herzig
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. J Schriber
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. PL McCarthy Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Simon, M., Hahn, T., Ford, L. et al. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin. Bone Marrow Transplant 27, 627–633 (2001). https://doi.org/10.1038/sj.bmt.1702854

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702854

Keywords

This article is cited by

Search

Advanced search

Quick links